Selective Bioactivity of Fungal Secondary Metabolites as a Framework for Targeted Drug Discovery

Introduction: Fungal secondary metabolites remain an important source of structurally diverse molecules with pharmacological potential, yet conventional natural-product discovery has often separated fungal biology, chemical discovery and biological screening into largely sequential activities. This separation can obscure metabolites that are produced only under particular ecological or culture conditions, promote repeated isolation of known compounds, and make it difficult to connect a biological phenotype with the constituent responsible for it. Objectives: The central argument of this Perspective is that selective bioactivity should be treated as an information-rich property of fungal metabolites rather than as a weaker form of broad-spectrum activity. Methods: We therefore propose an integrated framework that begins with ecological and taxonomic selection of fungal systems, assesses biosynthetic potential, actively explores metabolite expression, applies metabolomics and dereplication before extensive purification, and then links biological activity to chemical identity and mechanism. Results: The framework also reconciles phenotypic and target-based screening: phenotypic assays are valuable for discovering unexpected biology, whereas target-oriented assays become increasingly informative after a selective phenotype has been reproduced and chemically attributed. We distinguish five evidentiary stages—differential response, reproducibility, chemical attribution, mechanistic selectivity and pharmacological selectivity—and emphasize that genomic potential does not establish metabolite expression, metabolite detection does not establish biological activity, and biological activity does not establish drug candidacy. Conclusions: Thermophilic fungi, including Malbranchea cinnamomea, illustrate why environmental adaptation, cultivation conditions and chemical diversity should be incorporated into discovery design. The proposed framework is intended to move fungal natural-product research from activity-led isolation alone toward an integrated, evidence-linked strategy for targeted drug discovery.

Authors

Publication Details

Journal
Journal of chemical health risks
Published
2026-11-13
Primary Topic
Microbial Natural Products and Biosynthesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selective Bioactivity of Fungal Secondary Metabolites as a Framework for Targeted Drug Discovery

Shanthipriya Ajmera
Journal of chemical health risks
Microbial Natural Products and Biosynthesis
article

Selective Bioactivity of Fungal Secondary Metabolites as a Framework for Targeted Drug Discovery

Shanthipriya Ajmera
article en

Abstract

Introduction: Fungal secondary metabolites remain an important source of structurally diverse molecules with pharmacological potential, yet conventional natural-product discovery has often separated fungal biology, chemical discovery and biological screening into largely sequential activities. This separation can obscure metabolites that are produced only under particular ecological or culture conditions, promote repeated isolation of known compounds, and make it difficult to connect a biological phenotype with the constituent responsible for it. Objectives: The central argument of this Perspective is that selective bioactivity should be treated as an information-rich property of fungal metabolites rather than as a weaker form of broad-spectrum activity. Methods: We therefore propose an integrated framework that begins with ecological and taxonomic selection of fungal systems, assesses biosynthetic potential, actively explores metabolite expression, applies metabolomics and dereplication before extensive purification, and then links biological activity to chemical identity and mechanism. Results: The framework also reconciles phenotypic and target-based screening: phenotypic assays are valuable for discovering unexpected biology, whereas target-oriented assays become increasingly informative after a selective phenotype has been reproduced and chemically attributed. We distinguish five evidentiary stages—differential response, reproducibility, chemical attribution, mechanistic selectivity and pharmacological selectivity—and emphasize that genomic potential does not establish metabolite expression, metabolite detection does not establish biological activity, and biological activity does not establish drug candidacy. Conclusions: Thermophilic fungi, including Malbranchea cinnamomea, illustrate why environmental adaptation, cultivation conditions and chemical diversity should be incorporated into discovery design. The proposed framework is intended to move fungal natural-product research from activity-led isolation alone toward an integrated, evidence-linked strategy for targeted drug discovery.

Journal of chemical health risks
Microbial Natural Products and Biosynthesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon